Treatment with an Antibody Against VGamma4 T Cells Reduces Rheumatoid Arthritis Symptoms in Mice
Tech ID:
07-06
Summary
Successful treatment of autoimmune disorders continues to be an unmet challenge. Scientists at National Jewish Health have identified a subset of gamma delta T cells that is active in the pathogenesis of rheumatoid arthritis. These cells produce IL-17, which is associated with inflammatory damage in rheumatoid arthritis, certain cancers, and is a major player in chronic autoimmune diseases. Targeting this small subset of T cells offers a unique way to limit inflammation and treat autoimmune diseases or cancer.
Potential Applications
Rheumatoid arthritis, cancer, other autoimmune and allergic diseases
Advantages of Invention
Targeting a small subset of gamma delta T cells will have fewer side-effects than depleting IL-17 using antibody based technology and won't disrupt the bodies ability to function in other diseases.
State of Development
Our scientists have shown in a collagen-induced arthritis murine model:
- Increased numbers of activated Vgamma4 cells in active disease
- Vgamma4 cells were major producers of the inflammatory cytokine, IL-17
- Administration of a monoclonal antibody targeting Vgamma4 T cells in mice resulted in a 42% decrease in RA histological parameters and a significant decrease in autoantibodies
Licensing Status
- Available for licensing.
For Further Information, Contact:
Emmanuel Hilaire, PhD
Manager
Technology Transfer Office
National Jewish Health
1400 Jackson Street, Room M206b
Denver, CO 80206
Voice: 303.398.1262
Fax: 303.270.2352
HilaireE@njhealth.org
